PMC:7252008 / 0-376 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"3","span":{"begin":46,"end":50},"obj":"Gene"},{"id":"4","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"5","span":{"begin":78,"end":87},"obj":"Disease"},{"id":"27","span":{"begin":264,"end":282},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"Gene:3569"},{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"MESH:C000657245"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:D007239"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":204,"end":214},"obj":"Body_part"},{"id":"T2","span":{"begin":246,"end":250},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":246,"end":250},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"T2","span":{"begin":78,"end":87},"obj":"Disease"},{"id":"T3","span":{"begin":204,"end":234},"obj":"Disease"},{"id":"T4","span":{"begin":236,"end":239},"obj":"Disease"},{"id":"T5","span":{"begin":264,"end":272},"obj":"Disease"},{"id":"T6","span":{"begin":273,"end":282},"obj":"Disease"},{"id":"T7","span":{"begin":326,"end":329},"obj":"Disease"},{"id":"T8","span":{"begin":356,"end":359},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":215,"end":225},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T2","span":{"begin":246,"end":250},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T3","span":{"begin":246,"end":250},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":0,"end":2},"obj":"Chemical"},{"id":"T2","span":{"begin":46,"end":48},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_49882"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A3","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":204,"end":225},"obj":"http://purl.obolibrary.org/obo/GO_0042116"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":3},"obj":"Sentence"},{"id":"T2","span":{"begin":4,"end":87},"obj":"Sentence"},{"id":"T3","span":{"begin":89,"end":101},"obj":"Sentence"},{"id":"T4","span":{"begin":102,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":273,"end":282},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection\n\nDear Editor,\nWe thank Cunningham et al. [1] and Ruscitti et al. [2] for their commentary on our article [3] on the Macrophage activation syndrome (MAS)-like lung pathology in COVID-19 pneumonia. In order to clarify the classification of MAS, we proposed two types of MAS that fit along t"}